10-Q: Seres Therapeutics Completes Sale of VOWST Business, Focuses on Pipeline Development

Seres Therapeutics finalized the sale of its VOWST business to Nestl Health Science, shifting its focus to advancing its pipeline, particularly SER-155.

Summary

• Seres Therapeutics completed the sale of its VOWST business to Nestl Health Science for an upfront payment of $100 million, a prepaid milestone of $60 million, and future milestone payments tied to sales targets.
• The company will also receive installment payments of $50 million on January 15, 2025 and $25 million on July 1, 2025, contingent on compliance with a Transition Services Agreement.
• Seres will share 50/50 in the net profit or loss of VOWST sales in the US and Canada until December 31, 2025.
• The company retired its senior secured debt facility with Oaktree Capital Management in connection with the sale.
• Seres is now focusing on advancing SER-155, a live biotherapeutic for preventing infections in immunocompromised patients, and other pipeline programs.
• The company reported a net loss from continuing operations of $110.1 million for the nine months ended September 30, 2024.
• As of September 30, 2024, Seres had cash and cash equivalents of $66.8 million and an accumulated deficit of $962.5 million.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern and will require additional funding by the fourth quarter of 2025.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The sale of VOWST and the promising SER-155 data are positive, but the going concern warning and the need for additional funding are significant concerns. The overall sentiment is cautiously negative.

Positives

• The sale of the VOWST business provides Seres with a significant cash infusion.
• The company has retired its debt with Oaktree Capital Management.
• SER-155 Phase 1b study showed promising results in reducing bloodstream infections and antibiotic use.
• The company is now focused on its wholly-owned pipeline of live biotherapeutic candidates.

Negatives

• The company has incurred significant losses since its inception and expects to continue to do so.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will require additional funding by the fourth quarter of 2025.
• The company is now a smaller, less diversified company.

Risks

• The total amount of installment and milestone payments from the VOWST sale is subject to various risks and uncertainties.
• The company may not realize the anticipated benefits of the VOWST sale and may face new challenges as a smaller company.
• The company will need additional funding to complete development of its product candidates and commercialize them.
• The company is a clinical-stage company and has incurred significant losses since its inception.
• The company relies on third parties for manufacturing, which increases the risk of insufficient quantities or unacceptable costs.
• The company has received a notice of failure to satisfy a continued listing rule from Nasdaq.
• The company is early in its development efforts and may not be successful in building a pipeline of product candidates.
• Clinical drug development is a risky, lengthy, and expensive process with an uncertain outcome.
• Delays or difficulties in patient enrollment could delay or prevent regulatory approvals.
• The company faces substantial competition, which may result in others commercializing competing products before or more successfully.
• The company may not be able to adequately protect its proprietary technology or obtain and maintain issued patents.
• The company's future success depends on its ability to retain key executives and attract qualified personnel.

Future Outlook

The company intends to use the proceeds from the VOWST sale to support the further advancement of SER-155 and other wholly-owned cultivated live biotherapeutic candidates. The company will require additional funding by the fourth quarter of 2025.

Management Comments

• Management plans to provide for the Companys capital requirements through financing or other strategic transactions, including potential business development transactions, and selling shares under the Companys at the market equity offering.
• Management has concluded that substantial doubt exists about the Companys ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.

Industry Context

The sale of the VOWST business reflects a strategic shift in the company's focus towards its pipeline of live biotherapeutic candidates, particularly SER-155, which targets a significant unmet need in preventing infections in immunocompromised patients. This move aligns with the growing interest in microbiome-based therapies and the potential for live biotherapeutics to address a range of diseases.

Comparison to Industry Standards

• The sale of VOWST to Nestl is a significant transaction in the microbiome therapeutics space, where few companies have achieved commercial success with live biotherapeutic products.
• The Phase 1b results for SER-155 are encouraging, particularly when compared to standard of care outcomes for allo-HSCT patients, where infection rates remain a major concern.
• The company's financial position, with a substantial accumulated deficit and the need for additional funding, is not uncommon for clinical-stage biotech companies, but the going concern warning is a significant concern.
• The company's reliance on third-party manufacturers is typical in the biotech industry, but it introduces risks related to supply and quality control.
• The company's intellectual property portfolio is extensive, but the uncertainty surrounding patent protection and potential challenges from competitors is a common risk in the biotech sector.

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against us and Nestl S.A., Nestl Health Science S.A., Nestl Health Science US Holdings, Inc. and SPN in the United States District Court for the District of Delaware alleging that the making, sale and use of VOWST infringes on U.S. Patent Nos. 9,433,652, 9,662,381, 9,808,519, 10,555,978, and 11,090,343.

Related Party Transactions

• The company completed the sale of its VOWST business to Socit des Produits Nestl S.A. (SPN).
• The company entered into a Transition Services Agreement with Nestl Enterprises S.A., an affiliate of SPN.
• The company entered into a securities purchase agreement with SPN, pursuant to which SPN purchased 14,285,715 shares of common stock.
• The company entered into a cross-license agreement with SPN.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern status and the need for additional funding.
• Employees may experience changes due to the restructuring and focus on new programs.
• Customers and patients may see changes in the availability of VOWST, now under Nestl's control.
• Suppliers and creditors may be impacted by the company's financial situation and strategic shift.

Next Steps

• The company will focus on advancing SER-155 and other wholly-owned cultivated live biotherapeutic candidates.
• The company will perform its obligations under the Transition Services Agreement with Nestl.
• The company will seek additional funding to support its operations.

Key Dates

Keywords

live biotherapeutics, microbiome, SER-155, VOWST, Nestl Health Science, clinical trials, infection, FDA approval, asset sale, biotechnology